Journal for ImmunoTherapy of Cancer (Nov 2023)

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

  • Enriqueta Felip,
  • Christian Mueller,
  • Martin Forster,
  • Tim Clay,
  • Matthew Krebs,
  • Frederic Triebel,
  • Enric Carcereny,
  • Ewa Kalinka,
  • Margarita Majem,
  • Bernard Doger,
  • Julio Peguero,
  • Chrystelle Brignone,
  • Igor Bondarenko,
  • Wade T Iams,
  • Manuel Cobo Dols,
  • Grygorii Ursol,
  • Gema Garcia Ledo,
  • Laia Vilà Martinez

DOI
https://doi.org/10.1136/jitc-2023-SITC2023.0595
Journal volume & issue
Vol. 11, no. Suppl 1

Abstract

Read online

No abstracts available.